| Revenue growth | 28% YoY stated; volume and realisation-led; EBITDA up only 3%. |
|---|---|
| Margins | EBITDA margin 18% in Q2 vs 22% in H1; raw material squeeze. |
| Demand visibility | Chlor-derivative demand rising; CPVC demand said to grow 13% annually. |
| Management confidence | Defensive on margins; blames West Asia and coal; outlook unquantified. |
Growth
Revenue +28% YoY, volume and pricing-led; EBITDA +3% to ₹136 Cr at 18% margin, so profit growth is weak.
Outlook
FY31 revenue estimate ₹5,000–5,100 Cr on ~₹4,200 Cr gross block; no FY27 growth figure given.
Risks
EBITDA margin 18% vs 22% in H1; coal and energy cost squeeze on chloro-alkali unresolved; net debt rose to ₹514 Cr.
Earnings Call Transcript filed with NSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹943.95
- Market cap
- ₹4,072 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 14.3×Sector 34.8×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Investor Presentation: Key Takeaways
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral Results Update
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Epigral Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 27.1% YoY
Epigral Ltd reported revenue from operations of ₹746 Cr (+27.0% YoY) and net profit of ₹65.1 Cr (+27.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +27.1% YoY
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral Legal & Regulatory
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
- Value
- ₹28.11 Cr
Epigral Board Meeting Date
Epigral schedules a board meeting on November 2, 2026 to approve unaudited Q2 and half-year results ended September 30, 2026. The notice is issued for shareholder information.